Engineering drug delivery systems,
from soft matter to clinical translation.

Home

We design drug delivery systems at the interface of soft matter engineering, nanomedicine, and oncology translation.

01 / News

What’s new.

Latest publications, awards and team updates from the laboratory.

June 2026

Guillaume Jacquot completes his PhD

Congratulations to Guillaume Jacquot for completing his PhD on hydrogel-based strategies for the controlled delivery of proteins.

April 2026

Launch of the PEPR BBTI Mono-CHEM project

The laboratory coordinates the PEPR BBTI Mono-CHEM project, in collaboration with the teams of Jean-Luc Perfettini, Suman Mitra, Véronique Decot, Benoit Favier and Eric Olmos, to develop a new cell therapy approach.

December 2025

ACS Nano publication on E3-K3 radioenhancers

Sebastian Jung and colleagues published a new application of the self-assembling E3-K3 peptide platform in ACS Nano, highlighting its potential as a modular radioenhancer system.

02 / Science

What we build.

We develop drug delivery systems and imaging tools for oncology, with a focus on injectable biomaterials, targeted nanoparticles, and clinically relevant therapeutic payloads.

Injectable biomaterials

Hydrogels and functional soft materials designed for local, sustained and more patient-friendly delivery of biologics and antibody-drug conjugates.

Targeted nanoparticles

Lipid and hybrid nanosystems engineered for controlled transport, tumor targeting and surface biofunctionalization with antibodies or other ligands.

Next-generation payloads

Therapeutic modalities including ADCs, immune-active agents, molecular glues and targeted protein degradation strategies adapted for delivery.

Imaging and theranostics

Diagnostic and image-guided platforms that connect nanoparticle design with treatment monitoring, biodistribution and translational decision-making.

Science

How we translate.

Our research strategy is designed to move from concept to biological validation, with each project guided by therapeutic relevance and translational potential.

Design

We identify an unmet medical need and tailor the payload and material architecture accordingly.

Engineer

We optimize formulation, conjugation, release, surface chemistry, and stability.

Validate

We assess efficacy, targeting, biodistribution, and safety in relevant models.

Translate

We prioritize manufacturability, route of administration, and clinical positioning.

03 / Team

Team.

A multidisciplinary team including biologists, chemists, physicists, pharmacists, and physicians.

Institut Strauss

Strasbourg

Permanent staff

Alexandre Detappe (HDR)
Xavier Pivot (HDR)
Lotfi Boudali
Pierre Coliat
Tristan Martin
Adeline Gasser
Sébastien Harlepp (HDR)
Mainak Banerjee
Sebastian Jung

PhD students

Julien Draussin
Guillaume Jacquot
Pedro Lopez
Elsa Barbe
Lauren Ramanantena
Mathilde Sohn
Clara Hummel
Abiram Selvaratnam
Louise Chollet (Oct. 26)
Juliette Seghesio (Oct. 26)

Postdoctoral fellows

Bohdan Kozibroda
Maria Guttierez-Blanco
Brigino Ralahy
Ana Pacheco (Oct. 26)

Interns

Sarra Hachaq
Olga Traissard
Duran Ekaitz
Abda Dareen
Gauthier Derex

Gustave Roussy

Paris